Incidence and clinical significance of ESR1 mutations in heavily pretreated metastatic breast cancer patients.

Niu, Jiaxin; Andres, Grant; Kramer, Kim; Kundranda, Madappa N; Alvarez, Ricardo H; Klimant, Eiko; Parikh, Ankur R; Tan, Bradford; Staren, Edgar D; Markman, Maurie

Niu, Jiaxin; Andres, Grant; Kramer, Kim; Kundranda, Madappa N; Alvarez, Ricardo H; Klimant, Eiko; Parikh, Ankur R; Tan, Bradford; Staren, Edgar D; Markman, Maurie.

Afiliação

Niu J; Department of Medical Oncology, Western Regional Medical Center at Cancer Treatment Centers of America (CTCA), Goodyear, AZ, USA.
Andres G; Department of Medical Oncology, Western Regional Medical Center at Cancer Treatment Centers of America (CTCA), Goodyear, AZ, USA.
Kramer K; CTCA Medicine and Science, Zion, IL, USA.
Kundranda MN; Department of Medical Oncology, Banner MD Anderson Cancer Center, Gilbert, AZ, USA.
Alvarez RH; Department of Medical Oncology, Southeastern Regional Medical Center at CTCA, Newnan, GA, USA.
Klimant E; Department of Medical Oncology, Eastern Regional Medical Center at CTCA, Philadelphia, PA, USA.
Parikh AR; Department of Medical Oncology, Eastern Regional Medical Center at CTCA, Philadelphia, PA, USA.
Tan B; Department of Pathology, Midwestern Regional Medical Center at CTCA, Zion, IL, USA.
Staren ED; Advanced Individual Medicine, Phoenix, AZ, USA.
Markman M; CTCA Medicine and Science, Philadelphia, PA, USA.

Onco Targets Ther ; 8: 3323-8, 2015.

Article em En | MEDLINE | ID: mdl-26648736

Palavras-chave

ESR1 mutation; breast cancer; endocrine therapy; genomic alteration; next-generation sequencing; resistance

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Idioma: En Ano de publicação: 2015 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google